44 related articles for article (PubMed ID: 15201230)
1. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.
Esposito A; Floridia M; d'Ettorre G; Pastori D; Fantauzzi A; Massetti P; Ceccarelli G; Ajassa C; Vullo V; Mezzaroma I
BMC Infect Dis; 2011 Dec; 11():341. PubMed ID: 22166160
[TBL] [Abstract][Full Text] [Related]
2. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE;
PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999
[TBL] [Abstract][Full Text] [Related]
3. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.
Balestre E; Ekouevi DK; Tchounga B; Eholie SP; Messou E; Sawadogo A; Thiébaut R; May MT; Sterne JA; Dabis F;
J Int AIDS Soc; 2016; 19(1):20044. PubMed ID: 26861115
[TBL] [Abstract][Full Text] [Related]
4. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.
Kumar S; Jin M; Ande A; Sinha N; Silverstein PS; Kumar A
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1363-75. PubMed ID: 22871069
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia.
Jevtović D; Salemović D; Ranin J; Brmbolić B; Pesić-Pavlović I; Zerjav S; Djurković-Djaković O
Open Virol J; 2009 Oct; 3():84-8. PubMed ID: 19911070
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Current CD4+ T-Cell Count Among Women of Reproductive Age on Antiretroviral Therapy in Public Hospitals, Southwest Ethiopia.
Belay AS; Manaye GA; Kebede KM; Abateneh DD
HIV AIDS (Auckl); 2021; 13():667-679. PubMed ID: 34168505
[TBL] [Abstract][Full Text] [Related]
7. The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Annison L; Dompreh A; Adu-Sarkodie Y
Ghana Med J; 2013 Dec; 47(4):164-70. PubMed ID: 24669021
[TBL] [Abstract][Full Text] [Related]
8. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.
Zaragoza-Macias E; Cosco D; Nguyen ML; Del Rio C; Lennox J
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):133-8. PubMed ID: 20156096
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz--still first-line king?
Best BM; Goicoechea M
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):965-72. PubMed ID: 18624683
[TBL] [Abstract][Full Text] [Related]
10. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
11. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
Waters L; Stebbing J; Jones R; Michailidis C; Sawleshwarkar S; Mandalia S; Bower M; Nelson M; Gazzard B
J Antimicrob Chemother; 2004 Aug; 54(2):503-7. PubMed ID: 15201230
[TBL] [Abstract][Full Text] [Related]
13. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
14. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
